hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
19. Inventories
Note
1. Finished goods in 2018 includes $1.8 million relating to deferred costs which has been reclassified from trade and other receivables; see note 2 for further details.
An expense of $1.6 million (2018 $0.1 million) has been charged to the income statement in the year for inventory write-downs. There were no reversals of prior period inventory write-downs (2018 nil).
No inventories are carried at fair value less costs to sell (2018 nil).
Table:
 | 2019 | 2018
 | $ million | $ million
Raw materials | 4.8 | 6.6
Work in progress | 1.2 | 1.2
Finished goods¹ | 14.6 | 19.7
 | 20.6 | 27.5


Question: What are the types of inventories in the table?
Answer: Raw materials, Work in progress, Finished goods
ITEM 6. SELECTED FINANCIAL DATA
The data for fiscal 2019, 2018 and 2017 and as of August 31, 2019 and 2018 are derived from the audited Consolidated Financial Statements and related Notes that are included elsewhere in this report. The data for fiscal 2016 and 2015 and as of August 31, 2017, 2016 and 2015 are derived from the audited Consolidated Financial Statements and related Notes that are not included in this report. The selected financial data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our Consolidated Financial Statements and related Notes included elsewhere in this report.
(1) Effective September 1, 2018, we adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) and eliminated our net revenues presentation and FASB ASU No. 2017-07, Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. Prior period amounts have been revised to conform with the current period presentation.
(2) Includes the impact of a $258 million charge associated with tax law changes recorded during fiscal 2018. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations for Fiscal 2018 Compared to Fiscal 2017—Provision for Income Taxes.”
(3) Includes the impact of a $312 million, post-tax, pension settlement charge recorded during fiscal 2017. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations for Fiscal 2018 Compared to Fiscal 2017—Pension Settlement Charge.”
(4) Includes the impact of a $745 million, post-tax, gain on sale of businesses recorded during fiscal 2016.
(5) Includes the impact of a $39 million, post-tax, pension settlement charge recorded during fiscal 2015.
Table:
 |  | Fiscal |  |  | 
 | 2019 | 2018 (1) (2) | 2017 (1) (3) | 2016 (1) (4) | 2015 (1) (5)
 |  | (in millions of U.S. dollars) |  |  | 
Income Statement Data |  |  |  |  | 
Revenues | $43,215 | $40,993 | $36,177 | $34,254 | $32,406
Operating income | 6,305 | 5,899 | 5,191 | 4,846 | 4,526
Net income | 4,846 | 4,215 | 3,635 | 4,350 | 3,274
Net income attributable to Accenture plc | 4,779 | 4,060 | 3,445 | 4,112 | 3,054
Earnings Per Class A Ordinary Share |  |  |  |  | 
Basic | $7.49 | $6.46 | $5.56 | $6.58 | $4.87
Diluted | 7.36 | 6.34 | 5.44 | 6.45 | 4.76
Dividends per ordinary share | 2.92 | 2.66 | 2.42 | 2.20 | 2.04


Question: What is the company's net income attributable to Accenture plc in 2017?
Answer: 3,445
ALTERNATIVE PERFORMANCE MEASURES – continued
Liquidity: TORM defines liquidity as available cash, comprising cash and cash equivalents, including restricted cash, as well as undrawn credit facilities.
TORM finds the APM important as the liquidity expresses TORM’s financial position, ability to meet current liabilities and cash buffer. Furthermore, it expresses TORM’s ability to act and invest when possibilities occur.
Table:
USDm | 2019 | 2018 | 2017
Cash and cash equivalents, including restricted cash | 72.5 | 127.4 | 134.2
Undrawn credit facilities | 173.1 | 278.7 | 270.7
Liquidity | 245.6 | 406.1 | 404.9


Question: How does TORM define liquidity?
Answer: TORM defines liquidity as available cash, comprising cash and cash equivalents, including restricted cash, as well as undrawn credit facilities
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risk is the risk of loss related to adverse changes in market prices, including interest rates and foreign exchange rates, of financial instruments. We are exposed to various types of market risks, including changes in interest rates and foreign currency exchange rates, in the normal course of business.
We use financial instruments, including variable rate debt and swaps and foreign exchange spot transactions, to manage risks associated with our interest rate and foreign currency exposures through a controlled program of risk management in accordance with established policies. These policies are reviewed and approved by our board of directors and stockholders’ meeting. Our treasury operations are subject to internal audit on a regular basis. We do not hold or issue derivative financial instruments for speculatively purposes.
Since export sales are primarily conducted in U.S. dollars, we had U.S. dollar-denominated accounts receivable of US$626 million as of December 31, 2019. As of the same date, we also had Japanese Yen-denominated accounts receivable of ¥14,266 million attributable to our Japanese operations and Renminbi-denominated accounts receivable of RMB¥710 million attributable to our China operations. We had U.S. dollar-, Japanese Yen- and Renminbi-denominated accounts payables of US$128 million, ¥7,193 million and RMB¥262 million, respectively, as of December 31, 2019.
Our primary market risk exposures relate to interest rate movements on borrowings and exchange rate movements on foreign currency denominated accounts receivable, capital expenditures relating to equipment used in manufacturing processes (including lithography, etching and chemical vapor deposition) and purchased primarily from Europe, Japan and the United States.
The following table provides information as of December 31, 2019 on our market risk sensitive financial instruments.
Table:
 | As of December 31, 2019 | 
 | Carrying Amount | Fair Amount
 | (in NT$ millions) | 
Time Deposits: Non-Trading Purpose | 62,320 | 62,320
Short-term Loans: Non-Trading Purpose | 12,015 | 12,015
Bonds: Non-Trading Purpose | 38,781 | 39,572
Long-term Loans: Non-Trading Purpose | 33,902 | 33,902


Question: What were the Time Deposits: Non-Trading Purpose carrying amount?
Answer: 62,320
Balance sheet
(a) Restated following adoption of IFRS 16. See note 1 and note 24 for further details
Goodwill and intangible assets increased to €31.0 billion (2018: €29.5 billion) mainly as a result of acquisitions which contributed €1.2 billion and favourable currency impact of €0.5 billion driven by strengthening of the US Dollar and Pound Sterling.
In current assets, cash and cash equivalents increased by €1.0 billion. The increase is primarily due to strong cash delivery in several countries which will be used to repay short term debt in due course.
Current and non-current financial liabilities increased by €1.5 billion as a result of commercial paper issue and bank borrowings.
The net pension plan deficit was lower than prior year by €0.7 billion as
gains from investment performance exceeded the increase in liabilities.
Table:
 | € million | € million
 | 2019 | 2018
 |  | (Restated)(a)
Goodwill and intangible assets | 31,029 | 29,493
Other non-current assets | 17,347 | 16,140
Current assets | 16,430 | 15,478
Total assets | 64,806 | 61,111
Current liabilities | 20,978 | 20,150
Non-current liabilities | 29,942 | 28,844
Total liabilities | 50,920 | 48,994
Shareholders’ equity | 13,192 | 11,397
Non-controlling interest | 694 | 720
Total equity | 13,886 | 12,117
Total liabilities and equity | 64,806 | 61,111


Question: What caused the increase in the cash and cash equivalents in 2019?
Answer: The increase is primarily due to strong cash delivery in several countries which will be used to repay short term debt in due course.
Profit or loss for the period after taxes
The current result of METRO China was reclassified in the consolidated income statement under the item ‘profit or loss for the period from discontinued operations after taxes’, taking into account necessary consolidation measures. To increase the economic meaningfulness of the earnings statement of the continuing sector, its shares in the consolidation effects were also included in the discontinued section of the earnings statement as far as they were related to business relations that are to be upheld in the long term even after the planned disposal. The previous year’s figures of the income statement were adjusted accordingly.
Profit or loss for the period from discontinued operations after taxes is attributable to the shareholders of METRO AG in the amount of €118 million (2017/18: €87 million). Noncontrolling interests account for €5 million of earnings (2017/18: €1 million).
In connection with the divestment process, expenses in the low 2-digit million euros range have been incurred to date.
As a result, profit or loss for the period from discontinued operations after taxes is made up as follows for METRO China:
Table:
€ million | 2017/2018 | 2018/2019
Sales | 2,680 | 2,901
Expenses | −2,563 | −2,736
Current earnings from discontinued operations before taxes | 117 | 165
Income taxes on gains/losses on the current result | −29 | −43
Current earnings from discontinued operations after taxes | 88 | 122
Gains/losses from the remeasurement or disposal of discontinued operations before taxes | 0 | 0
Gains/losses from the remeasurement or disposal of discontinued operations after taxes | 0 | 0
Profit or loss for the period from discontinued operations after taxes | 88 | 122


Question: How much of earnings does the Noncontrolling interests account for in FY2019?
Answer: €5 million
Audit and Non-Audit Fees
The following table presents fees billed for professional audit services rendered by PricewaterhouseCoopers LLP for the audit of the Company’s annual financial statements for the years ended June 29, 2019 and June 30, 2018 respectively, and fees billed for other services rendered by PricewaterhouseCoopers LLP and during those periods.
(1) Audit Fees are related to professional services rendered in connection with the audit of the Company’s annual financial statements, the audit of internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, reviews of financial statements included in the Company’s Quarterly Reports on Form 10-Q, and audit services provided in connection with other statutory and regulatory filings. Audit Fees in fiscal 2019 include fees for services performed by PricewaterhouseCoopers LLP in connection with the acquisitions of RPC Photonics, Inc. (“RPC”) and 3Z Telecom, Inc. (“3Z”). Audit Fees in fiscal 2018 include fees for the acquisitions of the AvComm and Wireless businesses of Cobham plc (“AW”) and Trilithic Inc. (“Trilithic”).
(2) Audit-Related Fees are related to due diligence services for our acquisition activities incurred in fiscal 2018.
(3) Tax Fees for fiscal 2019 and 2018 include professional services rendered in connection with transfer pricing consulting, tax audits, planning services and other tax consulting.
(4) All Other Fees are related to certain software subscription fees.
For fiscal year 2019, the Audit Committee considered whether audit-related services and services other than audit-related services provided by PricewaterhouseCoopers LLP are compatible with maintaining the independence of PricewaterhouseCoopers LLP and concluded that the independence of PricewaterhouseCoopers LLP was maintained.
Table:
 | Fiscal 2019 | Fiscal 2018
Audit Fees (1) | $3,631,575 | $3,784,488
Audit-Related Fees (2) | 0 | 359,000
Tax Fees (3) | 169,776 | 61,592
All Other Fees (4) | 4,500 | 3,600
Total | $3,805,851 | $4,208,680


Question: What is the total of Tax Fees and All Other Fees in 2019?
Answer: 174276
Calculation: 169,776+4,500
Cash Conversion Cycle
The following table presents the components of our cash conversion cycle for the fourth quarter of each of the past three fiscal years:
(1) Days sales outstanding, referred to as DSO, calculates the average collection period of our receivables. DSO is based on ending accounts receivable and net revenue for each period. DSO is calculated by dividing accounts receivable by average net revenue per day for the current quarter (91 days for each of the fourth quarters presented above). The year over year increases in DSO in the fourth quarter of fiscal 2019 and fiscal 2018 were primarily due to less favorable shipping linearity and, in the case of fiscal 2019, one of our major distributors choosing not to take advantage of an early payment discount.
(2) Days inventory outstanding, referred to as DIO, measures the average number of days from procurement to sale of our products. DIO is based on ending inventory and cost of revenues for each period. DIO is calculated by dividing ending inventory by average cost of revenues per day for the current quarter. The increase in DIO in the fourth quarter of fiscal 2019 compared to the corresponding period of fiscal 2018 was primarily due to higher levels of finished goods on hand at the end of fiscal 2019. Compared to the corresponding period in fiscal 2017, the decrease in DIO in the fourth quarter of fiscal 2018 was due primarily to strong product sales towards the end of the fourth quarter of fiscal 2018.
(3) Days payables outstanding, referred to as DPO, calculates the average number of days our payables remain outstanding before payment. DPO is based on ending accounts payable and cost of revenues for each period. DPO is calculated by dividing accounts payable by average cost of revenues per day for the current quarter. DPO for the fourth quarter of fiscal 2019 was relatively unchanged compared to the fourth quarter of fiscal 2018, while it increased compared to the corresponding period in fiscal 2017 was primarily the result of improved vendor payables management and extensions of payment terms with our suppliers.
(4) The cash conversion cycle is the sum of DSO and DIO less DPO. Items which may cause the cash conversion cycle in a particular period to differ include, but are not limited to, changes in business mix, changes in payment terms (including extended payment terms from suppliers), the extent of shipment linearity, seasonal trends and the timing of revenue recognition and inventory purchases within the period.
Table:
 | Three Months Ended |  | 
(in days) |  |  | 
Three Months Ended | April 26, 2019 | April 27, 2018 | April 28, 2017
Days sales outstanding (1) | 70 | 58 | 45
Days inventory outstanding (2) | 21 | 18 | 26
Days payables outstanding (3) | (87) | (90) | (56)
Cash conversion cycle (4) | 3 | (14 ) | 15
Days may not add due to rounding |  |  | 


Question: What was days inventory outstanding based on?
Answer: ending inventory and cost of revenues for each period.
(1) For a description and reconciliation of non-GAAP financial measures presented in this document, please see the Non-GAAP Financial Measures page, or visit the Black Knight Investor Relations website at https://investor.blackknightinc.com.
(2) In 2019, the effect of our indirect investment in The Dun and Bradstreet Corporation was a reduction of Net earnings of $73.9 million primarily due to the effect of its purchase accounting adjustments, restructuring charges and other non-operating charges. In 2017, Net earnings includes a one-time, non-cash net tax benefit of $110.9 million related to the revaluation of our deferred income tax assets and liabilities as a result of the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”).
Table:
(in millions, except per share data) | 2019 | 2018 | 2017
Revenues | $1,177.2 | $1,114.0 | $1,051.6
Adjusted Revenues(1) | $1,177.7 | $1,116.5 | $1,056.1
Earnings before equity in losses of unconsolidated affiliates | $182.8 | $168.5 | $254.2
Net earnings(2) | $108.8 | $168.5 | $254.2
Net earnings margin | 9.2% | 15.1% | 24.2%
Net earnings attributable to Black Knight | $108.8 | $168.5 | $182.3
Net earnings attributable to Black Knight, per diluted share | $0.73 | $1.14 | $1.47
Adjusted Net Earnings(1) | $295.4 | $277.9 | $209.6
Adjusted EPS(1) | $1.99 | $1.87 | $1.38
Adjusted EBITDA(1) | $583.4 | $542.5 | $505.8
Adjusted EBITDA Margin(1) | 49.5% | 48.6% | 47.9%


Question: What was the percentage change in revenues between 2018 and 2019?
Answer: 5.67
Calculation: (1,177.2-1,114.0)/1,114.0
NOTE 2. RIGHT-OF-USE ASSETS
The Company leases many assets, including land, buildings, houses, motor vehicles, machinery and equipment. Leases typically run up to a period of 5 years, some with an option to renew the lease after the end of the non-cancelable period. Lease payments are renegotiated on a periodic basis; timing is depending on the region and type of lease. The Company has not entered into any sub-lease arrangements.
Right-of-use assets
Table:
 | Land and buildings | Motor vehicles | Other machinery and equipment | Total
Balance January 1, 2019 | 23,579 | 1,488 | 620 | 25,687
Additions | 6,475 | 1,588 | 16 | 8,079
Transfer from property, plant and equipment | 459 | – | – | 459
Modifications and reassessments | 75 | 31 | (24) | 82
Retirements | – | – | – | –
Depreciation for the year | (6,057) | (1,008) | (268) | (7,333)
Foreign currency translation effect | 518 | 43 | 12 | 573
Balance December 31, 2019 | 25,049 | 2,142 | 356 | 27,547


Question: What is the change in total Balance from January 1, 2019 to December 31, 2019 
Answer: 1860
Calculation:  27,547 - 25,687
the company 2019s stock performance the following graph compares cumulative total return of the company 2019s common stock with the cumulative total return of ( i ) the nasdaq stock market-united states , and ( ii ) the nasdaq biotechnology index . the graph assumes ( a ) $ 100 was invested on july 31 , 2001 in each of the company 2019s common stock , the stocks comprising the nasdaq stock market-united states and the stocks comprising the nasdaq biotechnology index , and ( b ) the reinvestment of dividends . comparison of 65 month cumulative total return* among alexion pharmaceuticals , inc. , the nasdaq composite index and the nasdaq biotechnology index alexion pharmaceuticals , inc . nasdaq composite nasdaq biotechnology .

Table:
 | 7/02 | 7/03 | 7/04 | 7/05 | 12/05 | 12/06 | 12/07
alexion pharmaceuticals inc . | 100.00 | 108.38 | 102.64 | 167.89 | 130.56 | 260.41 | 483.75
nasdaq composite | 100.00 | 128.98 | 142.51 | 164.85 | 168.24 | 187.43 | 204.78
nasdaq biotechnology | 100.00 | 149.29 | 146.51 | 176.75 | 186.10 | 183.89 | 187.04
.

Question: what is the difference between the percent change between 7/02 and 7/03 of the investments into axion and the nasdaq composite?
Answer: -20.58%
Calculation: subtract(128.98, 100), divide(#0, 100), subtract(108.38, 100), divide(#2, 100), subtract(#3, #1)
NOTE 5 – PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment is summarized as follows (in thousands):
We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.
Depreciation expense was $66 thousand and $73 thousand for each of the years ended December 31, 2019 and 2018, respectively.
Table:
 | December 31, | 
 | 2019 | 2018
Building and improvements | $1,273 | $1,273
Scientific equipment | 597 | 598
Computer hardware and software | 106 | 107
Machinery and equipment | 274 | 275
Land and improvements | 162 | 162
Other personal property | 70 | 70
Office equipment | 27 | 27
 | 2,509 | 2,512
Less: accumulated depreciation | (1,969) | (1,906)
Total property, plant and equipment, net | $ 540 | $ 606


Question: How much assets were decapitalized from 2018 to 2019?
Answer: 3
Calculation: 2,512 - 2,509
Other Income (Expense), Net
Other expense, net decreased by $31 thousand in 2019 compared to 2018 as a result of the recognition of a $1.4 million loss on extinguishment related to the partial repurchase of our 2022 Notes and a $1.1 million increase in interest expense related to our convertible senior notes, offset by an increase of $2.7 million of interest income earned on our investment as a result of proceeds invested from our convertible note and common stock offerings.
Table:
 | Year Ended December 31, |  | Change | 
 | 2019 | 2018 | $ | %
 |  | (dollars in thousands) |  | 
Other expense, net | $ 4,597 | $ 4,628 | $ (31) | (0.7)%
% of revenue | 2% | 3% |  | 


Question: What was the % of revenue in 2019 and 2018?
Answer: 2, 3
The company utilizes certain of its financing receivables as collateral for nonrecourse borrowings. Financing receivables pledged as collateral for borrowings were $1,062 million and $710 million at December 31, 2019 and 2018, respectively. These borrowings are included in note P, “Borrowings.”
The company did not have any financing receivables held for sale as of December 31, 2019 and 2018.
Table:
($ in millions) |  |  |  | 
At December 31, 2018: | Investment in Sales-Type and Direct Financing Leases | Commercial Financing Receivables | Client Loan and Installment Payment Receivables/ (Loans) | Total
Financing receivables, gross | $6,846 | $11,889 | $13,614 | $32,348
Unearned income | (526) | (37) | (632) | (1,195)
Recorded investment | $6,320 | $11,852 | $12,981 | $31,153
Allowance for credit losses | (99) | (13) | (179) | (292)
Unguaranteed residual value | 589 | — | — | 589
Guaranteed residual value | 85 | — | — | 85
Total financing receivables, net | $6,895 | $11,838 | $12,802 | $31,536
Current portion | $2,834 | $11,838 | $ 7,716 | $22,388
Noncurrent portion | $4,061 | $    — | $ 5,086 | $ 9,148


Question: What is the average Recorded investment?
Answer: 10384.33
Calculation: 31,153 / 3
Performance Share Plan
The relevant disclosures in respect of the Performance Share Plan grants are set out below.
Table:
 | 2015 Grant | 2016 Grant | 2017 Grant | 2018 Grant | 2019 Grant
Grant date | 11th June | 5th April | 26th May | 4th April | 15th May
Mid market share price at grant date | 3,460.0p | 3,550.0p | 5,256.0p | 5,560.0p | 8,161.0p
Number of employees | 15 | 13 | 12 | 12 | 12
Shares under scheme | 70,290 | 69,890 | 62,356 | 60,899 | 60,626
Vesting period | 3 years | 3 years | 3 years | 3 years | 3 years
Probability of vesting | 71.5% | 70.8% | 73.1% | 73.5% | 74.1%
Fair value | 2,473.9p | 2,513.4p | 3,842.1p | 4,084.4p | 6,048.9p


Question: What are the relevant disclosures in the table pertaining to?
Answer: in respect of the Performance Share Plan grants